Here's why Natco Pharma share price gained over 4% on October …
WEB1 day ago · Natco Pharma share price: Pharmaceutical company Natco Pharma soared up to 4.34 per cent to hit an intraday high of Rs 1413.45 per share on Monday, October 7, 2024. The rise in Natco Pharma share price came after the company announced that Mylan Pharmaceuticals Inc and Novo Nordisk have reached a settlement of the US patent litigation related ...
Natco Pharma shares rise 4% on settlement order in US
WEB1 day ago · Natco Pharma advanced as high as 4 percent in the morning trade on October 7 on settlement order in the United States patent case over generic Ozempic products. The strong up move was seen in the ...
Natco Pharma shares gain after settlement in US patent
WEB1 day ago · Natco Pharma shares surged over 4% on Monday, October 7, after the company announced a settlement in the patent litigation pertaining to the generic version of Ozempic (Semaglutide) in the United States. The drug is used in the treatment of diabetes. Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for …
Natco Pharma settles US patent case over generic Ozempic
WEB1 day ago · At around 12.38 PM, Natco Pharma was trading 2.44% higher at ₹1,387 per piece, against the previous close of ₹1,353.95 on NSE. The counter touched an intraday high and low of ₹1,412.95, and ...
Amid GLP-1 craze, Novo and Mylan ink patent settlement in …
WEB23 hours ago · With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular type 2 diabetes drug Ozempic ...
Natco Pharma shares jump 4% amid weak broader markets; here' …
WEB1 day ago · Following the announcement, shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization close to Rs 25,000 crore.
Natco shares gain after antidiabetic drug partner Mylan, Novo …
WEB21 hours ago · Natco Pharma shares gained more than 3% on the back of its partner for development of generic anti-diabetic drug Ozempic (Semaglutide) Mylan Pharmaceuticals Inc and Novo Nordisk reaching ...
Natco Pharma soars after Mylan settles Ozempic patent dispute
WEB1 day ago · Hyderabad-based Natco Pharma is a vertically integrated pharmaceutical company. The companys consolidated net profit surged 59.05% year-on-year to Rs 668.5 crore in the first quarter of the current fiscal year (Q1 FY25), while revenue from operations increased by 19.47% to Rs 1,362.6 crore compared to the same period last year (Q1 FY24).
Natco Pharma shares jump 5% as company files for generic …
WEBAug 30, 2024 · Shares of Natco Pharma jumped nearly 5% to Rs 1,569 in Friday's intraday trade on BSE after the firm submitted a product application with the US health regulator for a generic product indicated for the treatment of metastatic non-small cell lung cancer.
Natco Pharma Limited Completes Transition of DASH Pharmaceuticals …
WEBJan 2, 2024 · PARSIPPANY, N.J.-- (BUSINESS WIRE)--Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, today announced that DASH Pharmaceuticals, a...